HeartWare International (NSDQ:HTWR) reported strong sales growth amid widening losses for the 4th quarter and 2011, and Wall Street showed some love.
The Framingham, Mass.-based heart pump maker raked in $82.8 million for the year ended Dec. 31, 2011, a 50% bump from $55.2 million in 2010. Losses, however, widened to $55.1 million, or $3.94 per diluted share. Analysts had forecast a loss of $3.17 per diluted share for 2011.
HeartWare touted a 50% jump in heart pump sales, with 932 systems sold worldwide in 2011 and a record 266 pumps sold in Q4, the most for any single quarter to date, according to SEC filings.
Fourth-quarter sales grew 11%, to a record-setting $23.1 million, but losses tripled to $21.6 million, or $1.53 per diluted share.
HeartWare president & CEO Doug Godshall attributed some of the spending to boosting commercial operations in Europe, investing in launch preparations for the company’s HVAD and preparing clinical trials for new platforms.
The HVAD system, designed for end-stage heart disease patients who are waiting for a transplant – a so-called “bridge-to-transplant” therapy – is set for review before the FDA’s circulatory system devices panel in April.
"We are intensely focused on preparing for our April 25, 2012, advisory committee panel meeting for our BTT pre-market approval application,” Godshall said in prepared remarks. "We have increased investment related to U.S. launch readiness and for preparation to commence human clinical trials of our next-generation platform, the MVAD system, in 2012.”
HeartWare saw a significant jump on The Street, with shares trading 7% higher at $76.41 as of 1 p.m. today.
Dentsply’s sales rise, profits slide
Sales rose but profits slid for Dentsply (NSDQ:XRAY) during the 4th quarter and 2011.
The York, Pa.-based dental device maker posted profits of $41.4 million, or 28 cents per diluted share, on sales of $738.0 million for the 3 months ended Dec. 31, 2011.
That compares with profits of $68.0 million, or 47 cents per diluted share, on sales of $568.2 million during the same period in 2010.
For the full year, Dentsply logged profits of $247.4 million, or $1.70 per share, on sales of $2.54 billion. That compares with profits of $267.3 million, or $1.82 per share, on sales of $2.22 billion during 2010. Read more
DJO Global’s sales, losses rise
DJO Global’s losses widened despite higher sales during the 4th quarter and 2011.
The San Diego-based medical device maker posted losses of $148.2 million on sales of $284.2 million for the 3 months ended Dec. 31, 2011.
That compares with losses of $11.4 million on sales of $249.8 million during the same period in 2010.
For the full year, DJO reported losses of $214.5 million on sales of $1.07 billion, compared with losses of $52.5 million on sales of $966.0 million during 2010. Read more
Drägerwerk’s Q4, 2011 sales, earnings drop
Drägerwerk AG (PINK:DRWKF) posted profits of €56.1 million (~$72.7 million) on sales of €635.3 million (~$823.3 million) for the 3 months ended Dec. 31, 2011.
That compares with profits of €74.1 million (~$96.0 million) on sales of €698.5 million (~$905.2 million) during the same period in 2010.
For the full year, Drägerwerk logged profits of €192.8 million (~$249.9 million) on sales of €2.18 billion (~$2.82 billion), compared with profits of €213.8 million (~$277.1 million) on sales of €2.56 billion (~$2.92 billion) during 2010.
Drägerwerk’s medical division’s sales were down for both periods, falling 30.6% to €58.3 million (~$75.6 million) during Q4, and 9.8% to €186.6 million (~$241.8 million) during 2011. Read more
Spectranetics swings to Q4 red
Spectranetics (NSDQ:SPNC) posted losses of $2.0 million, or 6 cents per share, on sales of $32.5 million for the 3 months ended Dec. 31, 2011.
That compares with profits of $513,000, or 2 cents per share, on sales of $29.3 million during the same period in 2010.
For the full year, the Colorado Springs-based medical device maker logged losses of $1.5 million, or 4 cents per share, on sales of $127.3 million. That compares with losses of 13.1 million, or 39 cents per share, on sales of $117.9 million during 2010. Read more
Q2 profits plunge for Unilens
Unilens (OTC:UVIC) posted profits of $282,000, or 12 cents per diluted share, on sales of $2.1 million for the 3 months ended Dec. 31, 2011.
That compares with profits of $350,000, or 15 cents per diluted share, on sales of $2.1 million during the same period in 2010. Read more